Loading...
Market
What will be the main outcome of the first clinical trial phase for the new Alzheimer's drug by the end of 2025?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Official trial results published by the drug developers or clinical trial registries
Story
New Drug Completes Preclinical Stage, Offers Hope for Rapid Alzheimer's Diagnosis
Oct 18, 2024, 09:18 AM
A new drug developed by specialists from Russian Peter the Great St. Petersburg Polytechnic University aims to protect Alzheimer's patients from memory loss. The drug's main substance, piperazine, is designed to target the brain effectively and has completed the preclinical stage. This development comes amid ongoing efforts to improve dementia diagnosis and treatment. Currently, it takes more than seven years on average to diagnose dementia, but new tests offer hope for rapid diagnosis. Experts are also exploring the potential of 'repurposed' drugs to limit the progression of dementia.
View original story
Similar markets
Statistically significant improvement • 25%
No significant difference • 25%
Worse outcomes • 25%
Trial terminated early • 25%
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Successful with minimal efficacy • 25%
Unsuccessful • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial discontinued • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Successful with measurable cognitive improvement • 25%
Partially successful with some cognitive improvement • 25%
Unsuccessful with no cognitive improvement • 25%
Trial canceled or postponed • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trials halted • 25%
Successful completion of Phase 1 • 25%
Partial success in Phase 1 • 25%
Failure in Phase 1 • 25%
No results announced • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%